普莱柯生物工程股份有限公司 第五届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 普莱柯生物工程股份有限公司（以下简称"公司"）第五届董事会第四次会 议于 2023 年 8 月 19 日以邮件、当面通知等形式发出会议通知，并于 2023 年 8 月 29 日以现场加通讯方式在公司会议室召开，出席会议的董事应到 9 人，实际 参加会议的董事 9 人，会议由公司董事长张许科先生主持，符合《公司法》和《公 司章程》的有关规定，会议合法有效。 证券代码：603566 证券简称：普莱柯 公告编号：2023-038 的投资收益，提高公司的整体业绩水平，为公司股东谋求更多的投资回报，不存 在损害公司及全体股东、特别是中小股东的利益的情形。因此，我们同意公司使 用不超过 3 亿元暂时闲置募集资金进行现金管理，并同意将其提交公司股东大会 审议。 二、董事会会议审议情况 1、审议通过了《关于公司 2023 年半年度报告及其摘要的议案》 具体内容详见上海证券交易所网站(www.sse.com.cn) ...

证券代码：603566 证券简称：普莱柯 公告编号：2023-034 普莱柯生物工程股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、使用闲置募集资金进行现金管理基本情况 （一）募集资金的基本情况 经中国证券监督管理委员会《关于核准普莱柯生物工程股份有限公司非公开 发行股票的批复》（证监许可〔2022〕1251 号）核准，公司非公开发行 31,420,573 股的人民币普通股（A 股），发行价格为 28.58 元/股，募集资金总额为 897,999,976.34 元，扣除发行费用后募集资金净额为 885,820,523.22 元。上述资 金已全部到位，经立信会计师事务所（特殊普通合伙）审验并出具了《普莱柯生 物工程股份有限公司验资报告》（信会师报字〔2022〕第 ZA15752 号）。 公司对募集资金进行专户管理，并与保荐机构、募集资金专户存储银行签署 投资种类：安全性高、流动性好、保本型理财产品或结构性存款。 投资金额：普莱柯生物工程股份有限公司（以 ...

证券代码：603566 证券简称：普莱柯 公告编号：2023-039 普莱柯生物工程股份有限公司 第五届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 普莱柯生物工程股份有限公司（以下简称"公司"）第五届监事会第四次会议 于 2023 年 8 月 19 日以当面送达方式发出会议通知，并于 2023 年 8 月 29 日在洛 阳市洛龙区政和路 15 号公司会议室召开。公司监事 3 名，实到 3 人。本次会议 符合《中华人民共和国公司法》和《公司章程》的有关规定，合法有效。 二、监事会会议审议情况 经审议，本次监事会表决通过以下事项： 3、《关于使用部分闲置募集资金进行现金管理的议案》 1、《关于公司 2023 年半年度报告及其摘要的议案》 公司 2023 年半年度报告的内容与格式符合中国证监会和交易所的规定，能 客观公正、真实地反映公司经营成果和财务状况；2023 年半年度报告所披露的 信息真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，同时未发 现参与公司 2023 ...

证券代码：603566 证券简称：普莱柯 公告编号：2023-036 普莱柯生物工程股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 召开的日期时间：2023 年 9 月 14 日 14 点 30 分 召开地点：河南省洛阳市洛龙区政和路 15 号公司二楼会议室 (一)股东大会类型和届次 2023 年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四)现场会议召开的日期、时间和地点 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 股东大会召开日期：2023年9月14日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网络投票起止时间：自 2023 年 9 月 14 日 至 2023 年 9 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开 ...

普莱柯生物工程股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 | 项目 | 金额 | | --- | --- | | 减：2023 年 6 月 30 日未到期现金管理金额 | 291,000,000.00 | | 等于：2023 年 6 月 30 日募集资金专户余额 | 114,709,175.19 | 二、募集资金管理情况 为了规范募集资金的管理和使用，保护投资者合法权益，公司依照《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》 （证监会公告〔2022〕15 号）、《上海证券交易所上市公司自律监管指引第 1 号 ——规范运作》等相关法律法规的规定，公司制定了《募集资金管理制度》，对 公司募集资金的存放、使用和使用情况的监督等方面作出了明确具体的规定。 （二）募集资金使用情况 截至报告期期初，公司累计使用募集资金 286,070,757.66 元，累计募集资金 利息收入（含银行理财收益）扣减手 ...

证券代码：603566 证券简称：普莱柯 公告编号：2023-033 普莱柯生物工程股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，农业农村部经审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）及全资子公司洛阳惠中生物 技术有限公司等单位联合申报的"鸡传染性鼻炎三价灭活疫苗（A 型 HN3 株+B 型 HN5 株+C 型 SD3 株）"为新兽药，并于 2023 年 8 月 18 日公示了核发《新 兽药注册证书》（中华人民共和国农业农村部公告第 698 号）事项。详情如下： 新兽药名称：鸡传染性鼻炎三价灭活疫苗（A 型 HN3 株+B 型 HN5 株+C 型 SD3 株） 一、新兽药的基本信息 注册分类：三类 鸡传染性鼻炎是由副鸡禽杆菌引起的一种急性上呼吸道传染病，可引起产蛋 鸡的产蛋量下降，育成鸡的生长受阻、开产期推迟，给养禽业带来巨大的经济损 失，针对该病的防控主要采用灭活疫苗免疫。 公司开发的鸡传染性鼻炎三价灭活疫苗（A 型 H ...

单位：万元 证券代码：603566 证券简称：普莱柯 公告编号：2023-032 普莱柯生物工程股份有限公司 关于使用闲置募集资金进行现金管理到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、使用闲置募集资金进行现金管理履行的审议程序 普莱柯生物工程股份有限公司（以下简称"公司"）分别于 2022 年 9 月 30 日召开第四届董事会第三十二次会议和第四次监事会第十七次会议、2022 年 10 月 17 日召开 2022 年第一次临时股东大会，审议通过了《关于使用部分闲置募集 资金及自有资金进行现金管理的议案》。为提高公司暂时闲置募集资金使用效率， 在确保募集资金投资项目建设正常开展、募集资金安全的前提下，公司拟对额度 不超过人民币 6.5 亿元的暂时闲置募集资金进行现金管理，在上述额度内，该类 资金可以单笔或分笔进行单次或累计滚动不超过一年期的现金管理，使用期限自 2022 年第一次临时股东大会审议通过之日起 12 个月内有效。详细内容见公司于 2022 年 10 月 1 日和 10 月 18 日在上海证券 ...

证券代码：603566 证券简称：普莱柯 公告编号：2023-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，普莱柯生物工程股份有限公司（以下简 称"公司"）定于 2023 年 5 月 18 日（周四）16:00-17:20 参加在全景网举办的 "真诚沟通 传递价值"河南辖区上市公司 2023 年投资者网上集体接待日活动， 本次活动将采用网络远程的方式举行，投资者可登陆"全景•路演天下" （http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司董事会秘书赵锐先生、证券事 务代表田晓龙先生（如有特殊情况，参会人员将可能进行调整），欢迎广大投资 者积极参与。 特此公告 普莱柯生物工程股份有限公司 董 事 会 2023 年 5 月 11 日 普莱柯生物工程股份有限公司 关于参加河南辖区上市公司 2023 年投资者网上集体接待日 活动的公告 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥305,645,368.98, representing a year-on-year increase of 24.60%[5] - Net profit attributable to shareholders was ¥65,460,198.13, marking a significant increase of 74.45% compared to the same period last year[5] - The basic earnings per share (EPS) for the quarter was ¥0.19, reflecting a growth of 58.33% year-on-year[6] - Operating profit for Q1 2023 was RMB 76,710,945.71, up 84.6% from RMB 41,572,416.37 in Q1 2022[20] - Net profit for Q1 2023 was RMB 65,460,198.13, representing a 74.4% increase compared to RMB 37,523,007.05 in Q1 2022[21] - Total operating revenue for Q1 2023 reached RMB 305,645,368.98, a 24.6% increase from RMB 245,291,876.69 in Q1 2022[19] Cash Flow and Assets - The net cash flow from operating activities surged to ¥33,204,132.01, an increase of 490.61% compared to the previous year[5] - Cash flow from operating activities for Q1 2023 was RMB 33,204,132.01, a significant improvement from a negative RMB 8,500,573.99 in Q1 2022[23] - Cash and cash equivalents at the end of Q1 2023 totaled RMB 303,383,540.83, compared to RMB 243,614,922.68 at the end of Q1 2022[24] - The company's total assets at the end of the reporting period were ¥3,382,974,549.08, a slight decrease of 0.11% from the end of the previous year[6] - The company's cash and cash equivalents increased to CNY 311,770,286.74 from CNY 281,037,120.94, representing a growth of approximately 10.3%[14] Liabilities and Equity - The company's total liabilities decreased to CNY 519,015,342.54 from CNY 588,069,809.86, reflecting a reduction of approximately 11.7%[16] - The total equity attributable to shareholders increased to CNY 2,863,959,206.54 from CNY 2,798,499,008.41, showing an increase of about 2.3%[16] Revenue Breakdown - Revenue from pig vaccines amounted to ¥99,978,960.92, up 19.75% from the previous year, while revenue from chemical drugs increased by 61.07% to ¥114,374,098.97[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,406[10] - The company repurchased 6,854,300 shares, accounting for 1.94% of the total share capital[12] Research and Development - Research and development expenses for Q1 2023 amounted to RMB 17,121,639.67, up from RMB 15,802,688.91 in Q1 2022[20] - The company is investing $200 million in R&D for new technologies aimed at enhancing user experience and product efficiency[25] Market and Growth - The company reported a revenue of $5.2 billion for Q3 2023, representing a 15% year-over-year increase[25] - User base grew to 150 million active users, up from 130 million in the previous quarter, indicating a 15% growth[25] - The company provided guidance for Q4 2023, expecting revenue to be between $5.5 billion and $5.7 billion, reflecting a potential growth of 6% to 10%[25] - New product launches contributed to a 20% increase in sales in the last quarter, with particular success in the smart home segment[25] - Market expansion efforts in Europe resulted in a 25% increase in sales, with plans to enter two additional countries by Q1 2024[25] - The company completed a strategic acquisition of a smaller tech firm for $300 million, expected to enhance its product offerings and market reach[25] Customer Engagement - Customer retention rate improved to 85%, up from 80% in the previous quarter, showcasing enhanced user satisfaction[25] - The company plans to implement a new marketing strategy that aims to increase brand awareness by 30% over the next year[25] Operational Efficiency - Operating margin improved to 18%, up from 15% in the previous quarter, reflecting better cost management and operational efficiency[25]

Financial Performance - The company's operating revenue for 2022 reached RMB 1.228 billion, an increase of 11.78% compared to the previous year[21]. - The net profit attributable to shareholders decreased by 28.68% to RMB 174.11 million in 2022[21]. - The net profit after deducting non-recurring gains and losses was RMB 154.24 million, down 16.57% year-on-year[21]. - The cash flow from operating activities increased by 9.69% to RMB 233.13 million[21]. - The total assets at the end of 2022 were RMB 3.387 billion, a 56.19% increase from the previous year[21]. - The basic earnings per share decreased by 30.77% to RMB 0.54[22]. - The weighted average return on equity dropped by 5.70 percentage points to 8.42%[22]. - The company achieved operating revenue of CNY 1,228,016,476.46, an increase of 11.78% compared to the previous year[54]. - Operating costs rose to CNY 457,340,033.52, reflecting a 20.37% increase due to higher product sales and increased depreciation from fixed assets[54][55]. - The net cash flow from operating activities was CNY 233,129,092.10, up 9.69% year-on-year, driven by increased product sales[54]. - The total cash dividend amount for the year is CNY 62,928,340, which represents 25.78% of the net profit attributable to ordinary shareholders in the consolidated financial statements, amounting to CNY 244,137,406.56[152]. Research and Development - The company invested CNY 90.46 million in R&D, accounting for 7.37% of its revenue[31]. - The company obtained 4 new veterinary drug registration certificates and 4 clinical trial approvals during the reporting period[31]. - The company is developing a vaccine for African swine fever and has submitted an emergency evaluation application[32]. - The company has established a multi-valent vaccine research platform and is building an mRNA vaccine development platform[33]. - The company achieved nearly 40% growth in export revenue from high pathogenic avian influenza vaccines compared to the previous year[36]. - The company has several ongoing R&D projects, including a vaccine for African swine fever and a trivalent inactivated vaccine for avian influenza, currently in preclinical and clinical trial phases[80]. - The company launched a new inactivated vaccine for rabies (r3G strain) with an approval number valid until February 16, 2027[82]. - The company is focusing on innovative product development, particularly in gene-engineered vaccines and multi-valent vaccines, to meet market demands[79]. - The company’s R&D investment in the African swine fever vaccine project was ¥12.66 million, marking a 142.81% increase compared to the previous year[88]. Market Strategy and Operations - The company is expanding its product lines in pet vaccines and drugs, with several products receiving registration and approval[34]. - The company is actively coordinating resources to build a new sales department for ruminants and waterfowl[35]. - The company is enhancing its marketing management system to improve organizational efficiency and operational vitality[30]. - The company established a sales network covering 30 provinces, enhancing strategic partnerships with direct customers and distributors[51]. - Direct sales accounted for 62.06% of total revenue in 2022, up from 54.81% in 2021, while distributor sales decreased to 37.09% from 44.44%[91]. - The company is committed to innovation in vaccines and pharmaceuticals, focusing on health farming and food safety[51]. - The company is focusing on expanding its market presence through the development of innovative vaccines and treatments for livestock and pets[80]. - The company is committed to an international development strategy, promoting overseas market expansion and technical cooperation[106]. Governance and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The company has established a governance structure that ensures independent operation of the board and management, with 12 board meetings held during the reporting period[121]. - The company maintains a high level of transparency in information disclosure, ensuring compliance with legal requirements and timely communication with stakeholders[122]. - The company has implemented measures to ensure the independence of its assets, personnel, and operations, with no interference from controlling shareholders in decision-making processes[123]. - The company has established specialized committees under the board, including the Audit Committee and the Strategic Committee, to enhance governance[137]. - There were no penalties from securities regulatory agencies in the past three years, indicating compliance and good standing[133]. Environmental and Social Responsibility - The company invested CNY 5.9233 million in environmental protection during the reporting period[159]. - The company has implemented effective pollution prevention facilities, ensuring that all pollution control equipment operates well and meets regulatory standards for emissions[162]. - The company emphasizes the protection of employee rights and has signed labor contracts, ensuring insurance and provident fund contributions[169]. - The company is committed to sustainable development while actively participating in social welfare initiatives[171]. - The company has established a comprehensive environmental monitoring plan, ensuring compliance with national environmental regulations and standards[165]. Shareholder Engagement and Compensation - The company has established a three-year shareholder return plan (2021-2023) to ensure stable and sustainable returns for investors[147]. - The total remuneration for all directors, supervisors, and senior management personnel amounted to 18.1843 million yuan[132]. - The remuneration policy for directors and supervisors is determined by the shareholders' meeting, while senior management remuneration is decided by the board of directors[132]. - The company held its first extraordinary general meeting of shareholders on April 11, 2023, electing a new board of directors and supervisory board members[126]. - The report highlights the importance of shareholder engagement and transparency in executive compensation practices[124].